

TITAN PHARMACEUTICALS INC

Form 8-K

October 31, 2011

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act 1934

Date of Report (Date of earliest event reported): October 25, 2011

## Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

Delaware  
(State or Other Jurisdiction of

0-27436  
(Commission

94-3171940  
(IRS Employer

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

Incorporation)

File Number)

Identification No.)

**400 Oyster Point Blvd., Suite 505,**

**South San Francisco, CA**  
**(Address of Principal Executive Offices)**

**Registrant's telephone number, including area code: 650-244-4990**

**94080**  
**(Zip Code)**

**(Former Name or Former Address, is Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On October 26, 2011, Titan Pharmaceuticals, Inc. (the Company ) issued a press release providing initial feedback from its pre-NDA meeting with the U.S. Food and Drug Administration ( FDA ).

The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release dated October 26, 2011

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: President

Dated: October 31, 2011

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated October 26, 2011